The demo reached both equally its Major endpoints, with semaglutide two.4 mg demonstrating statistically major and excellent enhancements in liver fibrosis without worsening of steatohepatitis, together with resolution of steatohepatitis with no worsening of liver fibrosis in people with MASH when compared to placebo.oneWhat's this? Test "Don't for